This segment focuses on the discovery and development of oral covalent small molecule drugs for the treatment of diabetes and obesity. Research and development activities include the proprietary FUSION™ System for discovering, designing, and developing novel product candidates. The company is currently advancing icovamenib and BMF-650. The therapeutic area covers endocrinology, specifically targeting GLP-1R. The patient impact aims to improve the lives of individuals suffering from diabetes and obesity by providing effective and accessible treatments. Market positioning is as a clinical-stage biopharmaceutical company with a focus on innovative therapies. Future opportunities include potential strategic partnerships or acquisitions upon positive data readouts and expansion into additional metabolic disease indications. Regulatory and clinical aspects involve ongoing clinical trials and seeking regulatory approvals for new drug candidates. Partnerships and collaborations are sought to accelerate drug development and commercialization.

This segment focuses on the development of novel therapies for various cancers. The primary research and development activities involve the use of the proprietary FUSION™ System to discover and develop oral covalent small molecule drugs. The company's lead product candidate, BMF-219, is an irreversible inhibitor of menin, a transcriptional regulator in oncogenic signaling. The therapeutic areas covered include multiple cancers. The patient impact aims to provide effective treatment options for patients with genetically defined cancers. Market positioning is as a clinical-stage biopharmaceutical company with a focus on innovative therapies. Future opportunities include expanding the pipeline with additional oncology drug candidates and exploring strategic partnerships. Regulatory and clinical aspects involve conducting clinical trials and seeking regulatory approvals. The company has a patent for GTPase KRAS inhibitors.